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Abstract 
Background: Survival outcome after developing brain metastasis is poor and there is an unmet need to 
identify factors that can promote brain metastasis. Granulocyte-colony stimulating factor (G-CSF) is 
given to support neutrophil recovery after myelosuppressive chemotherapy to some patients. However, 
there is emerging evidence that neutrophils can promote metastasis, including through the formation of 
neutrophil extracellular traps (NETs), scaffolds of chromatin with enzymes expelled from neutrophils to 
the extracellular space. In animal models, G-CSFs can induce NETs to promote liver and lung metastasis. 
The primary objective of this study was to test the association between G-CSF use and the later incidence 
of brain metastasis. 
Methods: Patients with de novo Stage IV breast cancer, without known brain metastasis at the time of 
initial diagnosis, were identified from electronic medical records covering the period from 1/1/2013 to 
12/31/2020 at Northwell Health. Univariate and multivariate logistic regression models were used to test 
the association between variables of interest, including G-CSF use, and brain metastasis.  
Results: A total of 78 patients were included in the final analysis. Among those 78 patients, 24 patients 
(30.8%) had received G-CSF along with chemotherapy at least once. In logistic regression models, G-CSF 
use was not a significant factor to predict brain metastasis (OR 1.89 [95%CI 1.89-5.33]; P=0.23). 
Interestingly, in multivariate logistic models, pulmonary embolism (PE)/deep venous thrombosis (DVT) 
was a significant predictive factor of brain metastasis (OR 6.74 [95%CI 1.82-25.01]; P=0.004) (38.5% vs 
21.5%). 
Conclusions: The use of G-CSF was not associated with increased risk of brain metastasis in patients 
with de novo Stage IV breast cancer. Interestingly, PE/DVT, which can be associated with elevated NETs, 
was associated with brain metastasis. Further studies are warranted to determine whether DVT/PE with 
or without elevated NETs levels in the blood, is predictive of developing brain metastasis in patients with 
de novo Stage IV breast cancer. 
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Introduction 
In the United States, breast cancer is the most 
common newly diagnosed non-cutaneous cancer and 
the second most common cause of cancer-related 








chemotherapy, including with anthracycline based 
regimens and taxane, along with surgery and 
radiation therapy is the current standard of care for 
localized breast cancers [2]. 
Granulocyte colony stimulating factor (G-CSF) 
has been recommended by the National 
Comprehensive Cancer Network (NCCN) [2] for dose 
dense regimens with a high likelihood of causing 
treatment-related neutropenia, such as the above 
mentioned anthracycline based regiments. Filgrastim 
(Neupogen®) and pegfilgrastim (Neulasta®) are 
manufactured forms of G-CSF commonly used to 
stimulate the bone marrow to produce mature 
granulocytes as well as proliferation and 
differentiation of neutrophil precursors. These 
manufactured forms of G-CSF are given to support 
the recovery from myelosuppression after cytotoxic 
chemotherapies or to treat febrile neutropenia. A 
randomized trial showed that prophylactic G-CSF use 
significantly decreased the risk of febrile neutropenia 
(1% vs. 17%, G-CSF vs. placebo) and febrile 
neutropenia-related hospitalization (1% vs 14%, 
G-CSF vs. placebo) in patients with breast cancer [3]. 
G-CSF clearly has clinical benefits in the 
short-term, but the long-term consequences of G-CSF 
treatment are less clear. A clinical study showed that 
high expression levels of endogenous G-CSF in 
triple-negative breast cancer are associated with poor 
overall survival [4]. In the 4T1 breast cancer mouse 
model, G-CSG blockage significantly reduced lung 
metastasis[5]. Several studies have also documented a 
direct link between G-CSF and formation of 
neutrophil extracellular traps (NETs; scaffolds of 
chromatin with enzymes expelled from neutrophils to 
the extracellular space) [5, 6]. When treating healthy 
mice with recombinant human G-CSF, an increase in 
neutrophils and platelet-activating factor stimulation 
resulted in dose-dependent increase in NETs in blood 
[7]. In the same study, treating 4T1 breast cancer 
bearing mice with an G-CSF neutralizing antibody 
prevented accumulation of neutrophils and reduced 
their sensitization toward NET formation in vitro [7].  
NETs were originally identified as a mechanisms 
of microorganisms killing [8, 9]. Several studies using 
murine models of breast cancer have documented that 
NETs promote metastasis to liver or lung [10], either 
by physically trapping circulating tumor cells or by 
promotion the exit from a quiescent state through 
extracellular matrix remodeling that turn on integrin 
signaling in the cancer cells [5, 11]. NETs can also 
promote cancer metastasis to liver by binding to a 
transmembrane receptor, CCDC25, on cancer cells 
[12] to stimulate invasion. Liver, lung, and brain are, 
together with bones, the most common sites of breast 
cancer metastasis. With regard to brain metastasis in 
breast cancer, a recent study demonstrated that 
phosholylation of EZH2, which is highly expressed in 
brain metastatic breast cancer cells, causes c-JUN 
upregulation and increased G-CSF secretion. This 
lead to increased neutrophil recruitment and 
increased formation of breast cancer brain metastasis, 
while blocking G-CSF resulted in fewer brain 
metastasis in multiple mouse models [13].  
In non-metastatic setting, the majority of the 
patients are expected to receive G-CSF as a part of 
standard care chemotherapy regimen. Thus, it is 
difficult to compare long-term outcome for patients 
who receive chemotherapy(s) with or without G-CSF 
in a retrospective study. In contrast, G-CSF is not 
routinely used in metastatic setting. Approximately 
15-30% of patients with metastatic breast cancer 
develop brain metastasis [14]. The survival outcome 
after patients develop brain metastasis is poor, with a 
median survival after diagnosis with brain metastasis 
of just 6-12 months [15, 16]. There is no drug 
approved specifically to treating brain metastasis, 
with the current standard of care limited to radiation 
and surgery. Therefore, identifying factors that may 
drive brain metastasis so that these can be targeted is 
a critical clinical need.  
In addition to their ability to promote metastasis, 
formation of NETs has also been linked to increased 
risk of thrombus formation including deep venous 
thrombosis (DVT) and pulmonary embolism (PE) [17]. 
A clinical study showed NETs throughout thrombi 
obtained from endovascular thrombectomy in all 
patients with ischemic stroke [18]. In murine 
experiments, it was further shown that NET 
formation can occur concomitant with venous 
thrombi in the lung [7]. Particularly regarding NETs 
and DVT/PE in patients with cancer, a prospective 
observational cohort study showed that in patients 
with cancer, elevated NET levels in blood are 
associated with high cumulative incidence of venous 
thromboembolism [19] and another study reported 
that NETs in blood is a prognostic factor in patients 
with terminal cancer [20]. Although there are many 
other causes of PE/DVT than excessive NET 
formation, presence of PE/DVT may be a clinical 
indicator of a particular high activation status of NET 
formation. However, its association with brain 
metastasis is unknown.  
Given the mounting evidence that G-CSF 
promote breast cancer metastasis in mouse models by 
acting on neutrophils to induce NETs as well as 
through other mechanisms, we hypothesized that 
patients who received G-CSF along with 
chemotherapy(s) have higher incidence of brain 
metastasis than those who did not receive G-CSF. The 
primary objective of this study was to test for a 




potential association between G-CSF use and the 
incidence of brain metastasis. The secondary 
objectives were to test the association between G-CSF 
use and brain metastasis free survival and overall 
survival (OS) and to test for an association between 
PE/DVT and brain metastasis and G-CSF use in 
patients with de novo stage IV disease without brain 
metastasis at the time of diagnosis.  
Methods 
Study population 
This retrospective chart review study was 
approved by the Institutional Review Board (protocol 
number: 20-0879) at the Feinstein Institutes for 
Medical Research at Northwell Health and a waiver of 
informed consent was granted based on the study’s 
retrospective nature. We reviewed the electronic 
medical record (EMR) covering the period from 
1/1/2013 to 12/31/2020 to identify patients with de 
novo stage IV breast cancer who 1) did not have 
confirmed brain metastasis at the time of diagnosis, 
and 2) had been treated with at least one cycle of any 
type of chemotherapy(s) with or without G-CSF at the 
Northwell Health Cancer Institute. G-CSF used was 
determined by each treatment physician based on 
clinical guidelines [2, 21]. We excluded patients 
diagnosed with co-existing or prior malignancies 
except for cutaneous malignancies, which had been 
appropriately surgically treated.  
Data collection 
From the EMR, we extracted age at diagnosis, 
ethnicity, menopausal status at diagnosis, histological 
type (ductal, lobular, or others), hormone receptor 
(HR) status, the human epidermal growth factor 2 
(HER2) receptor status, smoking status, existence of 
pulmonary embolism (PE) and/or deep venous 
thrombosis (DVT) which was defined any PE/DVT 
found after the initial diagnosis, hormonal therapy, 
HER2 targeted therapy, immunotherapy, and G-CSF 
use. HR positivity was defined as positivity for 
estrogen receptor (ER) and/or progesterone receptor 
(PR) by immunohistochemistry staining. ER and PR 
positivity was defined based on the American Society 
of Clinical Oncology (ASCO)/College of American 
Pathologists (CAP) guideline. HER2 positivity was 
defined as a HER2/CEP17 fluorescence in situ 
hybridization (FISH) ratio of ≥2.0 and/or an 
immunohistochemical (IHC) staining score of 3+ [22].  
Statistical analysis 
Standard descriptive statistics and frequency 
tabulation were used to summarize data. The 
chi-square test and Fisher’s exact test were used to 
evaluate the association between two categorical 
variables. The Kruskal-Wallis test was used to 
compare the distributions of continuous variables 
among different groups. Univariate and multivariate 
logistic regression models were used to investigate 
the association between each variable and incidence 
of brain metastasis. Univariate and multivariate cox 
proportional hazard models were used to investigate 
the association between each variable and brain 
metastasis free survival (BMFS) and OS. BMFS was 
defined as the time from initial diagnosis to that of 
brain metastasis or last follow-up. OS was defined as 
the time from the date initial diagnosis to that of death 
or last follow-up. Patients who have not experienced 
the event (brain metastasis or death) was censored at 
the time of last follow-up. Variables with 
p-values<0.05 in univariate analysis and G-CSF use 
were included in multivariate analysis. A 
Kaplan-Meier estimate with a log-rank test was used 
for BMFS. All tests were two-sided and p-values <0.05 
were considered statistically significant. All analyses 
were carried out using STATA ver. 14 software. 
Results 
Patient Characteristics 
A total of 78 patients were included in the final 
analysis. Among these 78 patients, 24 patients (30.8%) 
received G-CSF. There were no significant differences 
in variables of interest between patients treated with 
G-CSF and those who were not treated with G-CSF, 
except for HER2 targeted therapy: G-CSF use was 
associated with HER2 targeting therapy. Fourteen of 
24 patients (58.3%) who were treated with G-CSF 
received HER2 targeting therapy and 18 of 54 patients 
(33.3%) who were not treated with G-CSF received it 
(P=0.04). Baseline patient characteristics are show in 
Table 1.  
The incidence of brain metastasis 
A total of 23 patients (29.5%) developed brain 
metastasis during the follow-up period. Thirteen of 54 
patients treated without G-CSF use (24.1%) and 10 of 
24 patients treated with G-CSF use (41.7%), a 
difference was not statistically significant (P=0.28). 
Among 13 patients who were treated without G-CSF 
and developed brain metastasis, 6 patients had 
PE/DVT (46.1%) and among 10 patients who were 
treated with G-CSF and developed brain metastasis, 2 
patients had PE/DVT (20%). In univariate logistic 
regression models, G-CSF use was not a significant 
predictor of brain metastasis (OR 1.89 [95%CI 
1.89-5.33]; P=0.23) (Table 2). Interestingly, PE/DVT 
was significantly associated with brain metastasis (OR 
5.83 [95%CI 1.65-20.63]; P=0.006) (38.5% of patients 
with DVT/PE and 21.5% of those without developed 
brain metastasis). Since G-CSF use is the variable of 




our interest, we performed a multivariate analysis 
including G-CSF use and DVT/PE. In multivariate 
analysis, PE/DVT remained significant (OR 6.74 
[95%CI 1.82-25.01]; P=0.004). G-CSF was not 
significantly associated with brain metastasis in 
multivariate analysis either (OR 2.37 [95%CI 
0.77-7.28]; P=0.13). G-CSF use and PE/DVT were not 
associated with each other (P=0.744). 
 
Table 1. Baseline patient characteristics 
  G-CSF (%) (N=24)  No G-CSF (%) (N=54)  P-values 
       
Age (range, median)  29-76 (56)  29-93 (56)  0.87 
Gender       
 Female  24 (100)  51 (94.4)  0.55 
 Male  0 (0)  3 (5.6)   
Ethnicity       
 Caucasian  12 (50)  34 (63)  0.35 
 African American  4 (16.7)  12 (22.2)   
 Others  6 (25)  7 (13)   
 Unknown  2 (8.3)  1 (1.9)   
Menopausal status       
 Premenopause  9 (37.5)  24 (44.4)  0.4 
 Postmenopause  15 (62.5)  26 (48.1)   
 Unknown  0 (0)  4 (7.4)   
Smoking Status       
 Yes  6 (25)  17 (31.5)  0.53 
 No  18 (75)  36 (66.7)   
 Unknown  0 (0)  1 (1.9)   
Active PE/DVT       
 Yes  3 (12.5)  10 (18.5)  0.74 
 No  21 (87.5)  44 (81.5)   
Hormonal Status       
 Positive  16 (66.7)  43 (79.6)  0.22 
 Negative  8 (33.3)  11 (20.4)   
HER2 status       
 Positive  14 (58.3)  20 (37)  0.08 
 Negative  10 (41.7)  34 (63)   
Histology       
 Ductal  18 (75)  39 (72.2)  0.75 
 Lobular  3 (12.5)  4 (7.4)   
 Others  2 (8.3)  7 (13)   
 Unknown  1 (4.2)  4 (7.4)   
Hormone treatment       
 Yes  15 (62.5)  40 (74.1)  0.3 
 No  9 (37.5)  14 (25.9)   
HER2 treatment        
 Yes  14 (58.3)  18 (33.3)  0.04 
 No  10 (41.7)  36 (66.7)   
Immunotherapy       
 Yes  6 (25)  6 (11.1)  0.17 
 No  18 (75)  48 (88.9)   
 
Brain metastasis free survival (BMFS) and 
overall survival (OS) 
There was no significant difference in BMFS 
between patients treated with or without G-CSF 
(Log-rank P=0.35) (Figure S1). G-CSF was neither a 
significant factor in predicting BMFS in univariate 
(HR, 1.33 [95% CI, 0.57-3.1]; P = 0.52) or multivariate 
cox proportional hazard models (HR, 0.85 [95% CI, 
0.32-2.22]; P = 0.74) (Table S1). However, PE/DVT 
was associated with short BMFS in multivariate cox 
proportional hazard models after adjusting for other 
significant variables (HR, 3.08 [95% CI, 1.1-8.6]; 
P=0.03).  
 
Table 2. Logistic regression model in incidence of brain 
metastasis 
  Univariate analysis  Multivariate analysis  
  Odds Ratio 
(95%CI) 
 P-Values  Odds Ratio 
(95%CI) 
 P-Values  
Age (range, 
median) 
 0.97 (0.94-1.01)  0.16      
Ethnicity          
 Caucasian  Ref        
 African American  1.45 (0.41-5.08)  0.57      
 Others  1.99 (0.54-7.35)  0.3      
Menopausal 
status 
         
 Premenopause  Ref        
 Postmenopause  0.49 (0.17-1.37)  0.18      
Smoking Status          
 No  Ref        
 Yes  0.84 (0.28-2.52)  0.75      
Active PE/DVT          
 No  Ref    Ref    
 Yes  5.83 (1.65-20.63)  0.006  6.74 (1.82-25.01)  0.004  
Hormonal Status          
 Negative  Ref        
 Positive  2.53 (0.66-9.76)  0.18      
HER2 status          
 Negative  Ref        
 Positive  0.86 (0.32-2.33)  0.77      
Histology          
 Ductal  Ref        
 Lobular  1.92 (0.39-9.56)  0.43      
 Others  0.73 (0.14-3.9)  0.72      
Hormone 
treatment 
         
 No  Ref        
 Yes  1.61 (0.51-5.51)  0.41      
HER2 treatment           
 No  Ref        
 Yes  1.07 (0.39-2.92)  0.9      
Immunotherapy          
 No  Ref        
 Yes  1.33 (0.36-4.98)  0.67      
G-CSF use          
 No  Ref    Ref    
 Yes  1.89 (0.67-5.33)  0.23  2.37 (0.77-7.28)  0.13  
 
With regard to OS, G-CSF use was not a 
significant variable (HR, 0.53 [95% CI, 0.21-1.31]; 
P=0.17) in univariate cox proportional hazard models 
(Table S2). HER2 positivity and HER2 target 
treatment were associated with short OS (HR, 0.29 
[95% CI, 0.11-0.75]; P=0.01, HR, 0.3 [95% CI, 0.11-0.79]; 
P=0.02, respectively) in univariate cox proportional 
hazard models, but neither variable was significant in 
multivariate cox proportional hazard models.  
Discussion 
In this retrospective study, we found no 
association between G-CSF use and the development 
of brain metastasis in patients with newly diagnosed 
de novo stage IV breast cancer. Interestingly, PE/DVT 
having occurred during follow-up period was 
associated with high incidence of brain metastasis.  




In the metastatic setting, G-CSF is currently used 
to support neutrophil recovery after myelosup-
pressive cytotoxic chemotherapies, prophylactic to 
maintain dose density or to treat febrile neutropenia 
[2]. A previous meta-analysis showed that length of 
hospitalization (HR 0.63 [95% CI 0.49 -0.82]; P=0.0006) 
and time to neutrophil recovery (HR 0.32 [95% CI 
0.23-0.46]; P< 0.00001) were both shorter in patients 
who were treated with G-CSFs than those who were 
not [23]. These are clear clinical benefits from giving 
G-CSF together with cytotoxic chemotherapies, but 
there are previous studies raising concerns that G-CSF 
use may promote cancer progression, and particularly 
metastasis, in the context of induced neutrocytosis 
[24, 25]. It has been shown that G‐CSF is expressed 
higher in triple negative breast cancer (TNBC) tumors 
compared to other subtypes (P < 0.001) [4, 26]. 
Furthermore, high G‐CSF levels in TNBC tumors are 
associated with short overall survival [4, 25, 27].  
Recently, it has been shown that one mean by 
which neutrophils can promote cancer progression is 
through the formation of NETs. This is of particular 
interest because G-CSF can induce neutrophils to 
form NETs [5] and because G-CSF promotes brain 
metastasis in a breast cancer mouse model [13].  
Our current study, including 78 patients, 
showed that patients who received G-CSF 
demonstrated numerically high incidence of brain 
metastasis compared to those who did not (24.1% 
versus 41.7%), but the difference was not statistically 
significant (P=0.28). This result remained similar in 
logistic regression models (OR 1.89 [95%CI 1.89-5.33]; 
P=0.23). A recent paper analyzing a total of 468 
patients showed that the levels of NETs in brain 
metastases were not significantly increased over the 
levels in the primary breast tumors and furthermore, 
the serum levels of NETs were not significantly 
elevated in patients with brain metastasis compared 
to patients without any type of metastasis [12]. 
Together, these data suggest that G-CSF induced 
NETs are not likely to play a major role in promotion 
as drivers of metastasis. However, among the 
variables of interest, PE/DVT was strongly associated 
with brain metastasis (OR 5.83 [95%CI 1.65-20.63]; 
P=0.006). The association between NET and 
thrombosis is well established [28, 29]. This result 
suggests that although G-CSF-induced NETs are 
likely to directly linked to brained metastasis, the 
presence of PE/DVT potentially triggered by NET, 
may be a surrogate predictive marker of future brain 
metastasis and this needs to be confirmed by further 
prospective studies, and if confirmed, studies to 
address the mechanism linking G-CSF use 
complicated with PE/DVT with brain metastasis need 
to be planned.  
There are several limitations in this study. First, 
this is a retrospective study. Second, it was necessary 
to focus on de novo stage IV breast cancer because 
earlier stage breast cancer almost always utilize 
G-CSF in neoadjuvant or adjuvant therapy but this 
may not represent the pattern of metastasis in other 
settings of patients with breast cancer. Third, sample 
size is small which is partially because our patients at 
Northwell system are taking annual screening 
regularly and tend to be diagnosed with earlier stage. 
Due to the good compliance with annual screening, 
the number of patients with de novo stage IV was 
relatively small and brain metastasis, our event of 
interest, is relatively rare. In our study, the total 
sample size is 78, with 13 of 54 having not been 
treated with G-CSF (24.1%) and 10 of 24 treated with 
G-CSF (41.7%) developed brain metastasis. With our 
sample size, the power to detect the 17.6% difference 
(41.7% vs 24.1%) using α=0.05 is 0.65. With α=0.05 and 
β=0.8, calculated sample sizes are 150, 79, and 47, 
respectively to detect 15% difference (40% vs 25%), 
20% difference (40% vs 20%), or 25% (40% vs 15%). 
Based on these calculations, we cannot exclude that 
G-CSF use causes an increase in brain metastasis 
incidence, up to about a 25% difference between 
treated and untreated.  
In conclusion, with the noted limitations, it is 
encouraging that the use of G-CSF was not associated 
with brain metastasis in patients with de novo Stage IV 
breast cancer, although a larger study is necessary to 
exclude an association. Interestingly, PE/DVT, which 
can be associated with elevated NETs, was associated 
with brain metastasis and further studies are 
warranted to determine more directly whether the 
presence of NETs in blood and DVT/PE are 
predictive of developing brain metastasis in patients 
with de novo Stage IV breast cancer.  
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